Recursion Pharmaceuticals

Recursion Pharmaceuticals is pioneering a TechBio approach to industrialize drug discovery, leveraging its proprietary Recursion OS—a closed-loop platform integrating automated wet labs, one of the world's largest fit-for-purpose biological datasets (>50 PB), and machine learning foundation models. The company has built a maturing clinical pipeline, with its lead asset, REC-4881 for Familial Adenomatous Polyposis (FAP), in Phase 2 and multiple other oncology programs in Phase 1/2. Its strategy centers on scaling its platform to systematically discover and develop first-in-class and best-in-class medicines, supported by strategic partnerships with pharmaceutical and technology leaders.

The Recursion Operating System (OS) is an integrated, closed-loop AI platform that industrializes drug discovery by combining automated wet labs generating petabytes of phenomic data with machine learning foundation models to map biology and design novel therapeutics.

Recursion competes with AI/ML peers like Exscientia and Schrödinger through its unique scale of integrated wet-lab data generation. For each clinical asset, it faces competition from traditional biotechs developing drugs for the same indications, differentiating on novel biology or engineered product profiles from its platform.